Enzyme-prodrug therapy for prosthetic joint repair
US7674454B2 · kind B2 · utility
4Cited by
1References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 4, 2005 |
| Grant date | Mar 9, 2010 |
| Priority date | — |
| Expiry date | Mar 4, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides adenoviral vectors and prodrugs for simultaneous, separate or sequential use in the destruction of interface tissue allowing subsequent recementing of loose prostheses in a minimally invasive manner.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.